On Nov 06, 2025, CRIS reported earnings of -0.49 USD per share (EPS) for Q3 25, beating the estimate of -0.58 USD, resulting in a 16.89% surprise. Revenue reached 3.18 million, compared to an expected 2.92 million, with a 8.87% difference. The market reacted with a -10.27% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 7 analysts forecast an EPS of -0.45 USD, with revenue projected to reach 3.25 million USD, implying an decrease of -8.16% EPS, and increase of 2.42% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Curis Inc's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Curis Inc reported EPS of -$0.49, beating estimates by 16.89%, and revenue of $3.18M, 8.87% above expectations.
How did the market react to Curis Inc's Q3 2025 earnings?
The stock price moved down -10.27%, changed from $1.46 before the earnings release to $1.31 the day after.
When is Curis Inc expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for Curis Inc's next earnings report?
Based on 7
analysts, Curis Inc is expected to report EPS of -$0.45 and revenue of $3.25M for Q4 2025.